Spruce Biosciences

SPRBPhase 2

South San Francisco, United StatesFounded 2017sprucebio.com

Spruce Biosciences is a patient-inspired biotech focused on serious, underserved neurological and endocrine conditions, with its lead program TA-ERT targeting MPS IIIB (Sanfilippo Syndrome Type B) in Phase 3. The company emphasizes a culture of innovation, trust, and urgency, driven by a leadership team with deep clinical and operational expertise. Spruce has been recognized as a 'Best Place to Work' in the Bay Area and is actively seeking strategic collaborations to advance its mission of delivering transformative therapies.

Market Cap

$80.1M

Founded

2017

Focus

Small Molecules

SPRB · Stock Price

USD 58.4011247.85 (-99.48%)

Historical price data

AI Company Overview

Technology Platform

Focus on enzyme replacement therapy (ERT) for lysosomal storage disorders, with a patient-inspired development approach prioritizing meaningful clinical outcomes.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
Tildacerfont/Placebo	Congenital Adrenal Hyperplasia	Phase 2
SPR001	Congenital Adrenal Hyperplasia	Phase 2
Tildacerfont + Placebo	Polycystic Ovary Syndrome	Phase 2
SPR001	Congenital Adrenal Hyperplasia	Phase 2
Tildacerfont/Placebo	Congenital Adrenal Hyperplasia	Phase 2

Opportunities

The primary opportunity is the potential first-in-class approval of TA-ERT for MPS IIIB, a fatal disease with no disease-modifying treatments.

Success could establish Spruce as a leader in ultra-rare neurological disorders.

The company's expressed focus on rare endocrine disorders, like Congenital Adrenal Hyperplasia, represents a significant pipeline expansion opportunity in another area of high unmet need.

Risk Factors

Key risks include Phase 3 clinical trial failure, regulatory challenges in ultra-rare diseases, dependence on external financing as a pre-revenue company, and potential commercialization hurdles for a highly specialized therapy.

The company's narrow focus on a single lead candidate creates significant binary risk.

Competitive Landscape

In MPS IIIB, Spruce faces limited direct competition due to the absence of approved disease-modifying therapies, positioning TA-ERT as a potential pioneer. However, other companies are exploring gene therapies and other modalities for Sanfilippo syndromes. In endocrine disorders, competition would be more established. Spruce differentiates through its urgent, patient-centric culture and focus on meaningful clinical outcomes.